Cargando…

Chemoradiation and consolidation chemotherapy for rectal cancer provides a high rate of organ preservation with a very good long-term oncological outcome: a single-center cohort series

AIM: To report long-term oncological outcomes and organ preservation rate with a chemoradiotherapy-consolidation chemotherapy (CRT-CNCT) treatment for locally advanced rectal cancer (LARC). METHOD: Retrospective analysis of prospectively maintained database was performed. Oncological outcomes of mid...

Descripción completa

Detalles Bibliográficos
Autores principales: Asoglu, Oktar, Bulut, Alisina, Aliyev, Vusal, Piozzi, Guglielmo Niccolò, Guven, Koray, Bakır, Barıs, Goksel, Suha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646475/
https://www.ncbi.nlm.nih.gov/pubmed/36352416
http://dx.doi.org/10.1186/s12957-022-02816-7
_version_ 1784827173062836224
author Asoglu, Oktar
Bulut, Alisina
Aliyev, Vusal
Piozzi, Guglielmo Niccolò
Guven, Koray
Bakır, Barıs
Goksel, Suha
author_facet Asoglu, Oktar
Bulut, Alisina
Aliyev, Vusal
Piozzi, Guglielmo Niccolò
Guven, Koray
Bakır, Barıs
Goksel, Suha
author_sort Asoglu, Oktar
collection PubMed
description AIM: To report long-term oncological outcomes and organ preservation rate with a chemoradiotherapy-consolidation chemotherapy (CRT-CNCT) treatment for locally advanced rectal cancer (LARC). METHOD: Retrospective analysis of prospectively maintained database was performed. Oncological outcomes of mid-low LARC patients (n=60) were analyzed after a follow-up of 63 (50–83) months. Patients with clinical complete response (cCR) were treated with the watch-and-wait (WW) protocol. Patients who could not achieve cCR were treated with total mesorectal excision (TME) or local excision (LE). RESULTS: Thirty-nine (65%) patients who achieved cCR were treated with the WW protocol. TME was performed in 15 (25%) patients and LE was performed in 6 (10%) patients. During the follow-up period, 10 (25.6%) patients in the WW group had regrowth (RG) and 3 (7.7%) had distant metastasis (DM). Five-year overall survival (OS) and disease-free survival (DFS) were 90.1% and 71.6%, respectively, in the WW group. Five-year OS and DFS were 94.9% (95% CI: 88–100%) and 80% (95% CI: 55.2–100%), respectively, in the RG group. For all patients (n=60), 5-year TME-free DFS was 57.3% (95% CI: 44.3–70.2%) and organ preservation-adapted DFS was 77.5% (95% CI: 66.4–88.4%). For the WW group (n=39), 5-year TME-free DFS was 77.5% (95% CI: 63.2–91.8%) and organ preservation-adapted DFS was 85.0% (95% CI: 72.3–97.8%). CONCLUSION: CRT-CNCT provides cCR as high as 2/3 of LARC patients. Regrowths, developed during follow-up, can be successfully salvaged without causing oncological disadvantage if strict surveillance is performed.
format Online
Article
Text
id pubmed-9646475
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96464752022-11-14 Chemoradiation and consolidation chemotherapy for rectal cancer provides a high rate of organ preservation with a very good long-term oncological outcome: a single-center cohort series Asoglu, Oktar Bulut, Alisina Aliyev, Vusal Piozzi, Guglielmo Niccolò Guven, Koray Bakır, Barıs Goksel, Suha World J Surg Oncol Research AIM: To report long-term oncological outcomes and organ preservation rate with a chemoradiotherapy-consolidation chemotherapy (CRT-CNCT) treatment for locally advanced rectal cancer (LARC). METHOD: Retrospective analysis of prospectively maintained database was performed. Oncological outcomes of mid-low LARC patients (n=60) were analyzed after a follow-up of 63 (50–83) months. Patients with clinical complete response (cCR) were treated with the watch-and-wait (WW) protocol. Patients who could not achieve cCR were treated with total mesorectal excision (TME) or local excision (LE). RESULTS: Thirty-nine (65%) patients who achieved cCR were treated with the WW protocol. TME was performed in 15 (25%) patients and LE was performed in 6 (10%) patients. During the follow-up period, 10 (25.6%) patients in the WW group had regrowth (RG) and 3 (7.7%) had distant metastasis (DM). Five-year overall survival (OS) and disease-free survival (DFS) were 90.1% and 71.6%, respectively, in the WW group. Five-year OS and DFS were 94.9% (95% CI: 88–100%) and 80% (95% CI: 55.2–100%), respectively, in the RG group. For all patients (n=60), 5-year TME-free DFS was 57.3% (95% CI: 44.3–70.2%) and organ preservation-adapted DFS was 77.5% (95% CI: 66.4–88.4%). For the WW group (n=39), 5-year TME-free DFS was 77.5% (95% CI: 63.2–91.8%) and organ preservation-adapted DFS was 85.0% (95% CI: 72.3–97.8%). CONCLUSION: CRT-CNCT provides cCR as high as 2/3 of LARC patients. Regrowths, developed during follow-up, can be successfully salvaged without causing oncological disadvantage if strict surveillance is performed. BioMed Central 2022-11-10 /pmc/articles/PMC9646475/ /pubmed/36352416 http://dx.doi.org/10.1186/s12957-022-02816-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Asoglu, Oktar
Bulut, Alisina
Aliyev, Vusal
Piozzi, Guglielmo Niccolò
Guven, Koray
Bakır, Barıs
Goksel, Suha
Chemoradiation and consolidation chemotherapy for rectal cancer provides a high rate of organ preservation with a very good long-term oncological outcome: a single-center cohort series
title Chemoradiation and consolidation chemotherapy for rectal cancer provides a high rate of organ preservation with a very good long-term oncological outcome: a single-center cohort series
title_full Chemoradiation and consolidation chemotherapy for rectal cancer provides a high rate of organ preservation with a very good long-term oncological outcome: a single-center cohort series
title_fullStr Chemoradiation and consolidation chemotherapy for rectal cancer provides a high rate of organ preservation with a very good long-term oncological outcome: a single-center cohort series
title_full_unstemmed Chemoradiation and consolidation chemotherapy for rectal cancer provides a high rate of organ preservation with a very good long-term oncological outcome: a single-center cohort series
title_short Chemoradiation and consolidation chemotherapy for rectal cancer provides a high rate of organ preservation with a very good long-term oncological outcome: a single-center cohort series
title_sort chemoradiation and consolidation chemotherapy for rectal cancer provides a high rate of organ preservation with a very good long-term oncological outcome: a single-center cohort series
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646475/
https://www.ncbi.nlm.nih.gov/pubmed/36352416
http://dx.doi.org/10.1186/s12957-022-02816-7
work_keys_str_mv AT asogluoktar chemoradiationandconsolidationchemotherapyforrectalcancerprovidesahighrateoforganpreservationwithaverygoodlongtermoncologicaloutcomeasinglecentercohortseries
AT bulutalisina chemoradiationandconsolidationchemotherapyforrectalcancerprovidesahighrateoforganpreservationwithaverygoodlongtermoncologicaloutcomeasinglecentercohortseries
AT aliyevvusal chemoradiationandconsolidationchemotherapyforrectalcancerprovidesahighrateoforganpreservationwithaverygoodlongtermoncologicaloutcomeasinglecentercohortseries
AT piozziguglielmoniccolo chemoradiationandconsolidationchemotherapyforrectalcancerprovidesahighrateoforganpreservationwithaverygoodlongtermoncologicaloutcomeasinglecentercohortseries
AT guvenkoray chemoradiationandconsolidationchemotherapyforrectalcancerprovidesahighrateoforganpreservationwithaverygoodlongtermoncologicaloutcomeasinglecentercohortseries
AT bakırbarıs chemoradiationandconsolidationchemotherapyforrectalcancerprovidesahighrateoforganpreservationwithaverygoodlongtermoncologicaloutcomeasinglecentercohortseries
AT gokselsuha chemoradiationandconsolidationchemotherapyforrectalcancerprovidesahighrateoforganpreservationwithaverygoodlongtermoncologicaloutcomeasinglecentercohortseries